Precision medicine—in which diagnosis and treatments are keyed to the genetic susceptibilities of individual cancers—has advanced to the point where it can now impact the care of a majority of children with brain tumors, a new study by investigators at Harvard Medical School and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center suggests. Funding for this project was provided by a partnership of non-profit foundations and government agencies including AKBTC.

To read more, please see:

Dana Farber/Boston Children’s News Release, January 19, 2017

Dana Farber Cancer Institute Spotlight Online, February 2017

Harvard Medical School, January 2017

Eureka Alert! January 19, 2017